Treatment of Cytomegalovirus (CMV) Pericarditis

Diagnosis Considerations

CMV-associated pericarditis is primarily found in immunocompromised patients, particularly those with HIV infection 1, 2
A comprehensive workup including histological, cytological, immunohistological, and molecular investigations in pericardial fluid and peri-/epicardial biopsies should be considered for definitive diagnosis (Class IIa, Level C recommendation) 1, 2
Routine viral serology is not recommended except for HIV and HCV testing (Class III, Level C recommendation) 1
PCR techniques can detect CMV nucleic acids in pericardial tissue and fluid, which is crucial for accurate diagnosis 2

The European Society of Cardiology recommends antiviral therapy for CMV pericarditis, with oral valganciclovir being preferred for less severe cases due to its excellent bioavailability and convenience 1, 3, 2
Intravenous ganciclovir is recommended for more severe cases or immunocompromised patients 3
Corticosteroids are generally contraindicated in viral pericarditis, as they can reactivate viral infections and lead to ongoing inflammation (Class III, Level C recommendation) 1, 3

The European Society of Cardiology guidelines suggest antiviral treatment similar to that for myocarditis for CMV pericarditis, though these treatments are still under evaluation 1, 3

Failure to identify CMV as the causative agent may lead to inappropriate corticosteroid use, which can worsen the condition 1, 3

PCR analysis of pericardial fluid or tissue is the preferred diagnostic method (Class IIa, Level B) to confirm CMV as the causative agent, as serology alone is insufficient, according to the European Society of Cardiology 4, 5
A four-fold rise in serum antibody levels is suggestive but not diagnostic, as noted by the European Heart Journal 4

The European Society of Cardiology guidelines suggest that specific antiviral treatments for CMV pericarditis are still under investigation, with oral valganciclovir and intravenous ganciclovir being considered, as mentioned in the European Heart Journal 4, 5
An alternative investigational approach is the hyperimmunoglobulin regimen, as noted in the European Heart Journal 4, 5, 6